peptides
PT-141 (Bremelanotide) 10mg
PT-141 (Bremelanotide) is a synthetic melanocortin-4 receptor agonist derived from Melanotan II. Research focuses on central nervous system pathways of sexual arousal, distinct from vascular-only mechanisms.
Research-observed benefits
- ›Libido and arousal response
- ›Central sexual pathway activation
- ›Rapid onset (30–60 min)
- ›Applicable to both sexes in research
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
Reconstitution helper
Suggested: 2 mL BAC water → 5.00 mg/mL
CAS Number
—
Purity
99%+
Molecular Formula
—
Stock
500 units
Order type
Purchase option
Quantity
Total
$50
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
PT-141 (Bremelanotide) 10mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Synthetic cyclic heptapeptide agonist of the melanocortin receptors (primarily MC4R, with MC1R activity). Acts centrally in the hypothalamus to modulate dopaminergic sexual arousal pathways — independent of vascular / PDE5 mechanisms.
How It Helps
Research models show increased sexual desire and arousal response in both male and female cohorts, including subjects unresponsive to PDE5 inhibitors, because the mechanism is upstream in the CNS rather than peripheral vasodilation.
Half-Life
~2 hours plasma; behavioral effects sustained 6–8 hours
Onset of Effects
Effects typically observed within 30–60 minutes of administration.
Administration
Subcutaneous injection — abdomen or thigh. 27–31G insulin syringe.
Storage
Lyophilized: store at –20°C, stable 24+ months. Reconstituted: refrigerate 2–8°C, use within 28 days.
Reconstitution Guide
10 mg vial + 2 mL bacteriostatic water → 5 mg/mL (0.5 mg per 0.1 mL). 1 mL BAC → 10 mg/mL for compact dosing. Swirl gently, do not shake.
Precise Dosing Protocols
Standard research dose
- Dose:
- 1.75 mg per administration
- Frequency:
- As-needed, ≤1 per 24h, ≤8 per month
- Duration:
- Ongoing in study window
- Notes:
- FDA-approved Vyleesi reference dosing
Titration entry
- Dose:
- 0.5–1 mg to assess tolerance
- Frequency:
- Single dose
- Duration:
- First 1–2 administrations
Stacks Well With
- ›Kisspeptin (HPG axis synergy)
- ›Standalone use is most common in libido research
Research-Observed Side Effects
- •Nausea (most common, dose-dependent)
- •Transient flushing
- •Headache
- •Mild transient blood-pressure elevation
- •Injection-site reaction
- •Darkening of skin/moles with repeated use (MC1R activity)
Translational Cautions
- •Uncontrolled hypertension in human translation
- •Cardiovascular disease models
- •Melanoma history (MC1R stimulation)
Cycling Guidance
Used as-needed rather than cycled. Research protocols typically cap at 8 doses per month to limit MC1R pigment effects.
Research Highlights
- ▸FDA-approved (2019) as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
- ▸Phase-2 and phase-3 trials demonstrate central-pathway efficacy in PDE5-non-responders.
- ▸Distinct mechanism from sildenafil/tadalafil — acts on desire, not just erectile response.